<sup>90</sup>Y-Edotreotide for Metastatic Carcinoid Refractory to Octreotide

Bushnell, David; O’Dorisio, Thomas M.; O’Dorisio, M. Sue; Menda, Yusuf; Hicks, Rodney J.; Cutsem, Éric Van; Baulieu, J. L.; Borson‐Chazot, Françoise; Anthony, Lowell; Benson, Al B.; Öberg, Kjell; Grossman, Ashley; Connolly, Mary; Bouterfa, Hakim; Li, Yong; Kacena, Katherine; LaFrance, Norman; Pauwels, Stanislas

doi:10.1200/jco.2009.22.8585

Cited by 287 publications

(181 citation statements)

References 28 publications

Supporting

Mentioning

165

Contrasting

Unclassified

Order By: Relevance

“…However, analysis of survival data showed that survival in patients with a partial response might be similar to that in patients with stable disease after PRRT (36)(37)(38)(39). With these findings in mind, for the evaluation of a response, one could consider disease control rates (complete response, partial response, and stable disease), which ranged from 62% to 95% in trials including only patients with progressive disease at baseline (38)(39)(40)(41)(42). Figure 2 shows the efficacy of PRRT in a patient with rectal NET with metastases to the liver.…”

Section: Efficacymentioning

confidence: 99%

Somatostatin Receptor 2–Targeting Compounds

Duijzentkunst

Bodei

2017

J Nucl Med

View full text Add to dashboard Cite

The molecular imaging and treatment of neuroendocrine tumors (NETs) with radiolabeled somatostatin analogs represent a milestone in the development of theranostic compounds. Whole-body scintigraphy with 111 In-pentetreotide has revolutionized the diagnosis and staging of NETs and the evaluation of treatment outcomes. At present, diagnostic accuracy with positron-emitting radionuclides is greater than 90%. Peptide receptor radionuclide therapy (PRRT) has become a well-accepted treatment for patients with welldifferentiated inoperable or metastatic NETs and disease progression after first-line treatment. Disease control rates (complete or partial remission or stable disease in patients with formerly progressive disease) of up to 95%, with a low incidence of long-term hematologic and renal toxicity, have been reported. In a recently published randomized trial, compared with intensified treatment of midgut NETs with longacting and repeatable octreotide, PRRT reduced the hazard of disease progression and death by 79%. Upcoming developments in PRRT include the use of somatostatin receptor antagonists and a-emitting radionuclides, which may further enhance treatment outcomes.

show abstract

Section: Efficacymentioning

confidence: 99%

Somatostatin Receptor 2–Targeting Compounds

Duijzentkunst

Bodei

2017

J Nucl Med

View full text Add to dashboard Cite

show abstract

“…The response rate to PRRT varies significantly depending on the location of the primary tumor. For example, an SST receptorpositive metastasized ileal NET exhibits a response rate which is much lower than SST receptor-positive metastasized pancreatic NET [26,27,29]. Given these observations, the concept of utilizing PRRT in all well to moderately differentiated gastroenteropancreatic NETs requires critical reassessment.…”

Section: Mechanism Of Action Of Radionuclidesmentioning

confidence: 99%

Whither peptide receptor radionuclide therapy for neuroendocrine tumors: an Einsteinian view of the facts and myths

Prasad

Bodei

Kidd

et al. 2014

Eur J Nucl Med Mol Imaging

View full text Add to dashboard Cite

“…[14][15][16][17] In addition, the majority of studies have shown excellent symptomatic response in >70% of patients. Time to progression in reported studies ranged from 13-29 months.…”

Section: Y-dotatate/dotatoc Anti-tumour Effectsmentioning

confidence: 99%

Molecular radiotheranostics for neuroendocrine tumours

Flux

Bomanji

2017

Clinical Medicine

View full text Add to dashboard Cite

This article discusses the important role of nuclear medicine imaging and therapy in the management of neuroendocrine tumours (NETs). Somatostatin receptor scintigraphy has a high impact on patient management versus conventional imaging. Molecular radiotherapy is an important part of the management of patients with NETs. Selection of patients for molecular radiotherapy in NETs is based on uptake on their radionuclide imaging study. The imaging agent has the same mechanism of uptake as the therapeutic agent. Thus, the imaging study preselects patients that are likely to concentrate radiation within their tumours. IntroductionNeuroendocrine tumours (NETs) represent a spectrum of tumours that can arise from various parts of the body and have variability in clinical presentation. They are often classified by embryonic origin into foregut, midgut and hindgut tumours. Foregut tumours develop in the respiratory tract, thymus, stomach, duodenum and pancreas; midgut tumours develop in the small bowel, appendix, caecum and ascending colon; hindgut tumours develop in the transverse colon, descending colon, sigmoid colon or rectum.1 NETs have a spectrum of presentations, ranging from well differentiated to poorly differentiated tumours, functioning to non-functioning and have variable proliferative activity.2 The tumour differentiation, grading (based on tumour proliferation and mitotic activity) and the site of primary tumour are important factors in making therapeutic decisions in management of NET patients.Unlike many cancers, large proportions of NETs tend to be slow growing and are not associated with increased metabolic activity. These are therefore not visualised on fludeoxyglucose (FDG) positron emission tomography/ computerised tomography (PET/CT). Other functional imaging techniques have thus been employed to stage NETs and determine suitability for molecular radiotherapy. Despite variability in presentation, NETs have similar properties in that the majority of well-differentiated and some high-grade tumours can concentrate neuroamines and have a high degree ABSTRACT Molecular radiotheranostics for neuroendocrine tumours of somatostatin receptor (SSR) expression. This high degree of SSR expression and neuroamine concentration can be exploited both in terms of imaging and therapy with radiolabelled somatostatin analogues and radiolabelled catecholamine analogue meta-iodobenzyl guanidine (MIBG). 3,4Selection of patients for molecular radiotherapy is based on uptake on their radionuclide imaging study. In nuclear medicine, theranostics is a combination of a diagnostic agent and a therapeutic agent where the target imaged/treated is the same. The imaging agent has the same mechanism of uptake as the therapeutic agent. Thus, the imaging study pre-selects patients that are likely to concentrate radiation within their tumours. The imaging and therapeutic radiopharmaceutical forms a theranostic pair. This article discusses the important role of radionculide imaging and radionculide therapy in the management of NETs based ...

show abstract

⁹⁰Y-Edotreotide for Metastatic Carcinoid Refractory to Octreotide

Abstract: (90)Y-edotreotide treatment improved symptoms associated with malignant carcinoid among subjects with no treatment alternatives. Treatment was well-tolerated and had an acceptable expected AE profile.

Cited by 287 publications

References 28 publications

Somatostatin Receptor 2–Targeting Compounds

Somatostatin Receptor 2–Targeting Compounds

Whither peptide receptor radionuclide therapy for neuroendocrine tumors: an Einsteinian view of the facts and myths

Molecular radiotheranostics for neuroendocrine tumours

Contact Info

Product

Resources

About

90Y-Edotreotide for Metastatic Carcinoid Refractory to Octreotide

Abstract: (90)Y-edotreotide treatment improved symptoms associated with malignant carcinoid among subjects with no treatment alternatives. Treatment was well-tolerated and had an acceptable expected AE profile.

Cited by 287 publications

References 28 publications

Somatostatin Receptor 2–Targeting Compounds

Somatostatin Receptor 2–Targeting Compounds

Whither peptide receptor radionuclide therapy for neuroendocrine tumors: an Einsteinian view of the facts and myths

Molecular radiotheranostics for neuroendocrine tumours

Contact Info

Product

Resources

About

⁹⁰Y-Edotreotide for Metastatic Carcinoid Refractory to Octreotide